Pfizer Animal Health Acquires Embrex

Pfizer Animal Health Acquires Embrex

Suggested Veterinary Products

Pfizer Animal Health has completed its acquisition of Embrex Inc., an international agricultural biotechnology company known for its Inovoject vaccine-delivery systems. The transaction has an aggregate equity purchase price of about $155 million.

Embrex, which is now a wholly-owned subsidiary of Pfizer, will continue to be based in Raleigh-Durham, N.C. Embrex common stock is no longer publicly traded and was de-listed from NASDAQ as the close of the market on Jan. 19.


Leave a Comment


Your email address will not be published. Required fields are marked *